A review of controlled studies with
nomifensine, performed outside the UK
by
Habermann W.
Br J Clin Pharmacol 1977;4Suppl 2:243S-248S

ABSTRACT

1. Double-blind controlled comparisons of nomifensine with placebo, imipramine, desipramine, viloxazine, nortriptyline, a combination of amitriptyline and chlordiazepoxide, and diazepam have been carried out in various parts of the world. 2. Dosage ranged from 50-225 mg daily, and treatment lasted from 2-26 weeks. 3. Nomifensine was shown to possess useful antidepressive activity, to counteract inhibition, to restore drive and to relieve anxiety. 4. Adverse reactions were uncommon, particularly anticholinergic effects, and nomifensine was not shown to cause sedation or to interact with alcohol. No withdrawal phenomena were observed after 6 months' treatment. 5. Nomifensine is not suitable for severely agitated patients.

Analgesia
Amineptine
Nomifensine: profile
Nomifensine dependence
Nomifensine versus impipramine
Nomifensine, bupropion and cocaine
Nomifensine and haemolytic anaemia
Nomifensine, noradrenaline and dopamine

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative

The Good Drug Guide
The Responsible Parent's Guide To
Healthy Mood Boosters For All The Family